About | Free Trial

Last Update

2016-04-14T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Elaine Mardis?

Dr. Elaine Mardis R.

Co-Director

Genome Sequencing Center

Direct Phone: (314) ***-****       

Email: e***@***.edu

Genome Sequencing Center

4444 Forest Park Boulevard

St. Louis, Missouri 63108

United States

Company Description

Founded in 2000, Genome Qu├ębec is a private, not-for-profit organization that funds research projects in genomics and proteomics. The organization is managing 21 large projects under a business plan worth $220 million, with the promise of possible spin-of ... more

Find other employees at this company (35)

Background Information

Employment History

Senior Research Scientist
Bio-Rad Laboratories Inc

Affiliations

Advisory Board Member
DNA Sequencing Inc

Chair of the Basic and Translational Sciences Committee
American College of Surgeons

Scientific Advisory Board Member
Ingenuity Systems Inc

Editorial Board Member
Genome Research

Board Member
Applied Biosystems Inc.

Member
American Society of Human Genetics

Education

B.S. degree
zoology
University of Oklahoma

Ph.D.

National Human Genome Research Institute

Ph.D.

The Genome Institute of Washington University

Ph.D.

Washington University

Ph.D.

Washington University School of Medicine

Ph.D.
Biochemistry and Chemistry
University of Oklahoma

PhD

Scripps Translational Science Institute

PhD

The Genome Institute at Washington University

Web References (196 Total References)


Elaine Mardis, Ph.D., ...

www.personalizedmedicinepartnerships.com [cached]

Elaine Mardis, Ph.D., Professor and Co-Director of The Genome Institute at Washington University School of Medicine, introduced exciting work in the design of patient-unique cancer vaccines. Such immunotherapies can even be combined with existing cancer drugs, e.g., checkpoint inhibitors, in priming strategies that "wake-up" the immune system prior to vaccination. She cited pediatric glioma, especially the recurrent setting, as an area of notable success to date.


The Official Blog of the Annual Personalized and Precision Medicine Conference - The Personalized/Precision Medicine Blog

www.personalizedmedicinepartnerships.com [cached]

Elaine Mardis, Ph.D., Professor and Co-Director of The Genome Institute at Washington University School of Medicine, introduced exciting work in the design of patient-unique cancer vaccines. Such immunotherapies can even be combined with existing cancer drugs, e.g., checkpoint inhibitors, in priming strategies that "wake-up" the immune system prior to vaccination. She cited pediatric glioma, especially the recurrent setting, as an area of notable success to date.


Elaine Mardis, Ph.D., ...

www.personalizedmedicinepartnerships.com [cached]

Elaine Mardis, Ph.D., Professor and Co-Director of The Genome Institute at Washington University School of Medicine, introduced exciting work in the design of patient-unique cancer vaccines. Such immunotherapies can even be combined with existing cancer drugs, e.g., checkpoint inhibitors, in priming strategies that "wake-up" the immune system prior to vaccination. She cited pediatric glioma, especially the recurrent setting, as an area of notable success to date.


Elaine Mardis, Ph.D., ...

www.personalizedmedicinepartnerships.com [cached]

Elaine Mardis, Ph.D., Professor and Co-Director of The Genome Institute at Washington University School of Medicine, introduced exciting work in the design of patient-unique cancer vaccines. Such immunotherapies can even be combined with existing cancer drugs, e.g., checkpoint inhibitors, in priming strategies that "wake-up" the immune system prior to vaccination. She cited pediatric glioma, especially the recurrent setting, as an area of notable success to date.


Elaine Mardis, Ph.D., ...

www.personalizedmedicinepartnerships.com [cached]

Elaine Mardis, Ph.D., Professor and Co-Director of The Genome Institute at Washington University School of Medicine, introduced exciting work in the design of patient-unique cancer vaccines. Such immunotherapies can even be combined with existing cancer drugs, e.g., checkpoint inhibitors, in priming strategies that "wake-up" the immune system prior to vaccination. She cited pediatric glioma, especially the recurrent setting, as an area of notable success to date.

Similar Profiles

Other People with this Name

Other people with the name Mardis

Ted Mardis
Rogers County Emergency Management Agency

Jenni Mardis
Unlimited Systems Inc

Bruce Mardis
BHH Affiliates LLC

Marcia Mardis
Florida State University

Lonnie Mardis
Lonnie Mardis

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory